BR55 Contrast Enhanced Ultrasound (CEUS) in Characterization of Ovarian Lesions
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2018
At a glance
- Drugs BR-55 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors Bracco Diagnostics
- 27 Nov 2018 Planned End Date changed from 1 Aug 2021 to 1 Jan 2022.
- 27 Nov 2018 Planned primary completion date changed from 1 Aug 2021 to 1 Dec 2021.
- 27 Nov 2018 Status changed from not yet recruiting to recruiting.